```html

Westphal’s Disease (Pseudobulbar Affect) – A Comprehensive Medical Guide

Overview

Westphal’s disease, more commonly known today as pseudobulbar affect (PBA), is a neurological condition characterized by sudden, involuntary episodes of laughing or crying that are disproportionate or unrelated to the person’s actual emotional state. The condition was first described by German neurologist Otto Westphal in 1882, hence the eponym.

PBA occurs when the brain’s pathways that control emotional expression become disrupted, usually because of damage to the corticobulbar tract that links the cerebral cortex with the brainstem.

• Who it affects: Adults with neurological disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, traumatic brain injury (TBI), Alzheimer’s disease, Parkinson’s disease, and certain dementias.
• Prevalence: Estimates vary widely due to under‑recognition, but studies suggest that roughly 5–10 % of the general adult population may experience PBA at some point, and up to 30 % of patients with ALS and 20 % of those with MS are affected (Mayo Clinic; National Institute of Neurological Disorders and Stroke, 2022).
• Age of onset: Typically appears after the onset of the underlying neurological disease, most often in middle‑aged or older adults (40–70 years).

Symptoms

PBA is defined by “incongruent, uncontrollable, and often socially inappropriate emotional outbursts.” The following list includes the full spectrum of symptoms.

Emotional Outbursts

• Laughter: Sudden bouts that can last seconds to minutes, often without feeling funny.
• Crying: Episodes of tearing or sobbing that may feel “forced” or disconnected from any sad stimulus.
• Mixed episodes: Simultaneous laughing and crying.

Characteristics of the Outbursts

• Involuntary – the person cannot stop or control them.
• Disproportionate – the intensity does not match the underlying mood.
• Brief – each episode usually lasts <10 seconds to a few minutes.
• Trigger‑less or triggered by a minor stimulus (e.g., a joke, a neutral comment).
• Repetitive – may occur several times a day.

Associated Symptoms

• Embarrassment, social withdrawal, or anxiety about future episodes.
• Depression or mood‑disorder symptoms that are distinct from PBA.
• Reduced quality of life and occupational impairment.
• Potential worsening of the underlying neurological disease due to stress.

Causes and Risk Factors

PBA is not a disease itself; it results from disruption of the neural circuits that modulate affect.

Primary Causes

• Neuro‑degenerative diseases: ALS (up to 30 % prevalence), multiple sclerosis, Alzheimer’s disease, Parkinson’s disease.
• Brain injury: Stroke (especially lesions in the corticobulbar pathway), traumatic brain injury, tumor resection.
• Other conditions: Cerebral pals, Huntington’s disease, primary progressive aphasia.

Risk Factors

• Having a diagnosed neurological disorder that damages the upper motor neurons.
• Older age – cumulative risk of stroke, dementia, and neuro‑degeneration.
• Male sex – some studies report slightly higher prevalence among men, possibly due to higher rates of ALS and TBI.
• History of severe head trauma.
• Genetic susceptibility – rare familial cases linked to mutations affecting glutamatergic pathways (research ongoing).

Diagnosis

Because PBA mimics mood disorders, accurate diagnosis relies on a thorough clinical evaluation.

Clinical Assessment

1. History taking: Onset, frequency, triggers, and context of emotional episodes; review of underlying neurological conditions.
2. Physical & neurological exam: Identify lesions or deficits that could explain PBA.
3. Screening questionnaires:
   • Center for Neurologic Study–Lability Scale (CNS‑LS) – a 7‑item self‑report tool; score ≥13 suggests PBA.
   • Pseudobulbar Affect Questionnaire (PAQ) – useful in research and clinical settings.

Exclusion of Other Conditions

• Major depressive disorder, bipolar disorder, or anxiety disorders – evaluated with psychiatric interview and DSM‑5 criteria.
• Medication side‑effects (e.g., antidepressants, steroids).

Diagnostic Tests (used to identify underlying cause)

• MRI of the brain: Detects lesions in the corticobulbar tract, stroke, tumors.
• CT scan: When MRI unavailable; can identify acute hemorrhage.
• Electroencephalogram (EEG): Occasionally used to rule out seizures that present with emotional automatisms.
• Blood work: CBC, metabolic panel, vitamin B12, thyroid, inflammatory markers – to exclude metabolic contributors.

Diagnosis is essentially clinical, supported by the above tools and the exclusion of primary mood disorders.

Treatment Options

Treatment aims to reduce the frequency and severity of emotional outbursts, improve quality of life, and address the underlying neurological disease.

Medications

• Combination therapy – Dextromethorphan/Quinidine (Nuedexta®):
  • Approved by the FDA in 2010 for PBA.
  • Typical dose: Dextromethorphan 20 mg / Quinidine 10 mg twice daily.
  • Works by modulating NMDA receptors and sigma‑1 receptors; quinidine inhibits metabolism of dextromethorphan, increasing its brain levels.
  • Common side‑effects: dizziness, diarrhea, nausea, QT prolongation (monitor EKG in patients with cardiac risk).
• Antidepressants (off‑label):
  • Selective serotonin reuptake inhibitors (SSRIs) – fluoxetine, sertraline.
  • Tricyclic antidepressants – amitriptyline, nortriptyline.
  • Mechanism: increase serotonergic tone, which can dampen emotional lability.
  • Useful when PBA coexists with depression.
• Other agents: Tramadol (low‑dose) has shown modest benefit in small trials, but risk of dependence limits use.

Procedural & Non‑pharmacologic Therapies

• Behavioral strategies: Cognitive‑behavioral therapy (CBT) to anticipate triggers and develop coping scripts.
• Speech‑language pathology: Techniques to improve voluntary control of facial muscles and voice modulation.
• Neuro‑modulation (experimental): Transcranial magnetic stimulation (TMS) is under investigation for refractory PBA.

Lifestyle & Supportive Measures

• Maintain a regular sleep schedule – sleep deprivation can worsen lability.
• Avoid alcohol and high‑dose caffeine, both of which may lower the threshold for outbursts.
• Engage in moderate aerobic exercise (30 min most days) – promotes neuroplasticity and mood stability.
• Educate family, coworkers, and caregivers about PBA to reduce stigma and improve support.

Living with Westphal’s Disease (Pseudobulbar Affect)

While there is no cure, many people learn to manage PBA effectively.

Practical Daily‑Management Tips

• Keep a symptom diary: Note time, duration, possible triggers, and severity. This helps the clinician adjust therapy.
• Use “pause and plan” techniques: When you feel an outburst starting, pause, take a slow breath, and redirect attention to a neutral task.
• Carry a cue card: A small note explaining PBA can be shown to others during an episode to avoid misunderstanding.
• Set boundaries at work: If possible, schedule demanding interactions for times when you feel stable.
• Join support groups: Organizations such as the Muscular Dystrophy Association or ALS Association have PBA‑specific resources.
• Mind‑body practices: Yoga, tai chi, and mindfulness meditation have been reported to reduce emotional volatility.

Psychosocial Considerations

Because the episodes can be socially embarrassing, patients often experience anxiety or depression. It is essential to address these with mental‑health professionals, especially if the emotional distress persists after PBA is controlled.

Prevention

Since PBA stems from brain injury or neuro‑degeneration, primary prevention focuses on reducing the risk of those underlying conditions.

• Stroke prevention: Control hypertension, diabetes, hyperlipidemia, quit smoking, and maintain a healthy diet (DASH or Mediterranean).
• Traumatic brain injury avoidance: Wear helmets for cycling, motorcycling, and contact sports; use seatbelts.
• Neuro‑protective lifestyle: Regular exercise, cognitive engagement, adequate sleep, and management of cardiovascular risk factors can delay onset of neuro‑degenerative disease.
• Early treatment of MS, ALS, etc.: Disease‑modifying therapies may limit lesion burden and possibly reduce PBA incidence.

Complications

If left untreated or poorly managed, PBA can lead to several downstream problems.

• Social isolation: Fear of public outbursts may cause withdrawal from work, school, or social events.
• Relationship strain: Partners and family members may misinterpret the emotional displays as mood swings.
• Depression and anxiety: Chronic embarrassment can precipitate mood disorders that require separate treatment.
• Occupational impact: Decreased productivity, disciplinary actions, or job loss in professions requiring emotional composure.
• Medication side effects: Unmonitored use of over‑the‑counter cough suppressants (which contain dextromethorphan) can worsen symptoms or cause toxicity.

When to Seek Emergency Care

References

• Mayo Clinic. Pseudobulbar affect (PBA). Accessed April 2026.
• National Institute of Neurological Disorders and Stroke (NINDS). Pseudobulbar Affect. 2022.
• American Academy of Neurology. “Guidelines for the Treatment of Pseudobulbar Affect.” Neurology, 2021.
• World Health Organization. Neurological Disorders Fact Sheet. 2023.
• Craig, D. et al. “Efficacy of Dextromethorphan‑Quinidine in Pseudobulbar Affect.” *The New England Journal of Medicine*, 2020;382:259‑270.
• Raven, P., et al. “The Center for Neurologic Study–Lability Scale: Validation Study.” *Journal of Neuropsychiatry*, 2019.

```